Exploring The Potential of CHRM4 as A Drug Target and Biomarker

Target Name: CHRM4

NCBI ID: G1132

CHRM4

Exploring The Potential of CHRM4 as A Drug Target and Biomarker

CHRM4, or acetylcholine receptor Muscarinic 4, is a G protein-coupled receptor located on the surface of various types of neurons in the central nervous system (CNS). It is involved in the regulation of various physiological processes that are critical for the maintenance of brain health and function. Unfortunately, despite its significant role in neurotransmission, CHRM4 has not yet been identified as a drug target or biomarker. In this article, we will explore the potential of CHRM4 as a drug target and highlight its potential as a biomarker for various neurological disorders.

Drug Target Potential

CHRM4 has been identified as a potential drug target due to its involvement in several important physiological processes. One of the key functions of CHRM4 is its role in modulating neurotransmission. CHRM4 is known to play a critical role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. This is important for the development and maintenance of learning and memory.

Another function of CHRM4 is its role in modulating pain perception. CHRM4 is known to play a critical role in the regulation of pain modulation, which is the ability of the brain to sense and respond to pain. This is important for the maintenance of tissue repair and regeneration.

In addition to its role in modulating neurotransmission and pain perception, CHRM4 is also involved in the regulation of sleep and wakefulness. This is important for the maintenance of cognitive function and overall brain health.

Biomarker Potential

CHRM4 has also been identified as a potential biomarker for several neurological disorders. One of the key challenges in the development of new treatments for neurological disorders is the lack of effective biomarkers that can be used to monitor the progression of disease and the effectiveness of new treatments.

CHRM4 is a potential biomarker for several neurological disorders, including Alzheimer's disease, Parkinson's disease, and chronic pain. These disorders are characterized by the progressive loss of brain cells and the development of neurodegeneration.

In addition to its potential as a biomarker, CHRM4 is also known to be involved in the regulation of neuroprotective enzymes. This is important for the maintenance of brain health and function, and may be a potential target for new treatments for neurological disorders.

Conclusion

In conclusion, CHRM4 is a G protein-coupled receptor that is involved in the regulation of various physiological processes in the CNS. Despite its significant role in neurotransmission, CHRM4 has not yet been identified as a drug target or biomarker. However, its potential as a drug target and biomarker make it an attractive target for future research. Further studies are needed to fully understand the role of CHRM4 in neurotransmission and the development of new treatments for neurological disorders.

Protein Name: Cholinergic Receptor Muscarinic 4

Functions: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase

The "CHRM4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CHRM4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets